Division für Molekulare & Zelluläre Pharmakologie

Publications

 

42.

An endoplasmic reticulum trafficking signal prevents surface expression of a voltage- and Ca2+-activated K+ channel splice variant.

Zarei MM, Eghbali M, Alioua A, Song M, Knaus HG, Stefani E, Toro L.

Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10072-7.

 
43.

Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency.

Sausbier M, Hu H, Arntz C, Feil S, Kamm S, Adelsberger H, Sausbier U, Sailer CA, Feil R, Hofmann F, Korth M, Shipston MJ, Knaus HG, Wolfer DP, Pedroarena CM, Storm JF, Ruth P.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9474-8.

 
44.

Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia.

Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG.

J Clin Invest. 2004 Feb;113(4):582-90.

 
45.

Subcellular localization of the delayed rectifier K(+) channels KCNQ1 and ERG1 in the rat heart.

Rasmussen HB, Møller M, Knaus HG, Jensen BS, Olesen SP, Jørgensen NK.

Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1300-9.

 
46.

A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1.

Angelo K, Korolkova YV, Grunnet M, Grishin EV, Pluzhnikov KA, Klaerke DA, Knaus HG, Møller M, Olesen SP.

Pflugers Arch. 2003 Oct;447(1):55-63.

47.

Localization of Ca2+ -activated big-conductance K+ channels in rabbit distal colon.

Hay-Schmidt A, Grunnet M, Abrahamse SL, Knaus HG, Klaerke DA.

Pflugers Arch. 2003 Apr;446(1):61-8.

48.

Regional differences in distribution and functional expression of small-conductance Ca2+-activated K+ channels in rat brain.

Sailer CA, Hu H, Kaufmann WA, Trieb M, Schwarzer C, Storm JF, Knaus HG.

J Neurosci. 2002 Nov 15;22(22):9698-707.

50.

Synthesis, characterization, and application of cy-dye- and alexa-dye-labeled hongotoxin(1) analogues. The first high affinity fluorescence probes for voltage-gated K+ channels.

Pragl B, Koschak A, Trieb M, Obermair G, Kaufmann WA, Gerster U, Blanc E, Hahn C, Prinz H, Schütz G, Darbon H, Gruber HJ, Knaus HG.

Bioconjug Chem. 2002 May-Jun;13(3):416-25.

51.

Ultrasensitive pharmacological characterisation of the voltage-gated potassium channel K(V)1.3 studied by single-molecule fluorescence microscopy.

Freudenthaler G, Axmann M, Schindler H, Pragl B, Knaus HG, Schütz GJ.

Histochem Cell Biol. 2002 Mar;117(3):197-202.

52.

Presynaptic Ca2+-activated K+ channels in glutamatergic hippocampal terminals and their role in spike repolarization and regulation of transmitter release.

Hu H, Shao LR, Chavoshy S, Gu N, Trieb M, Behrens R, Laake P, Pongs O, Knaus HG, Ottersen OP, Storm JF.

J Neurosci. 2001 Dec 15;21(24):9585-97.

53.

Potassium channels regulate tone in rat pulmonary veins.

Michelakis ED, Weir EK, Wu X, Nsair A, Waite R, Hashimoto K, Puttagunta L, Knaus HG, Archer SL.

Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1138-47.

54.

Developmental expression of the small-conductance Ca(2+)-activated potassium channel SK2 in the rat retina.

Klöcker N, Oliver D, Ruppersberg JP, Knaus HG, Fakler B.

Mol Cell Neurosci. 2001 Mar;17(3):514-20.

55.

Anomalous fluorescence enhancement of Cy3 and cy3.5 versus anomalous fluorescence loss of Cy5 and Cy7 upon covalent linking to IgG and noncovalent binding to avidin.

Gruber HJ, Hahn CD, Kada G, Riener CK, Harms GS, Ahrer W, Dax TG, Knaus HG.

Bioconjug Chem. 2000 Sep-Oct;11(5):696-704.

56.

Respiration and parturition affected by conditional overexpression of the Ca2+-activated K+ channel subunit, SK3.

Bond CT, Sprengel R, Bissonnette JM, Kaufmann WA, Pribnow D, Neelands T, Storck T, Baetscher M, Jerecic J, Maylie J, Knaus HG, Seeburg PH, Adelman JP.

Science. 2000 Sep 15;289(5486):1942-6.

57.

Generating a high affinity scorpion toxin receptor in KcsA-Kv1.3 chimeric potassium channels.

Legros C, Pollmann V, Knaus HG, Farrell AM, Darbon H, Bougis PE, Martin-Eauclaire MF, Pongs O.

J Biol Chem. 2000 Jun 2;275(22):16918-24.

58.

High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.

Eller P, Berjukov S, Wanner S, Huber I, Hering S, Knaus HG, Toth G, Kimball SD, Striessnig J.

Br J Pharmacol. 2000 Jun;130(3):669-77.

59.

Preparation of thiol-reactive Cy5 derivatives from commercial Cy5 succinimidyl ester.

Gruber HJ, Kada G, Pragl B, Riener C, Hahn CD, Harms GS, Ahrer W, Dax TG, Hohenthanner K, Knaus HG.

Bioconjug Chem. 2000 Mar-Apr;11(2):161-6.

60.

WIN 17317-3, a new high-affinity probe for voltage-gated sodium channels.

Wanner SG, Glossmann H, Knaus HG, Baker R, Parsons W, Rupprecht KM, Brochu R, Cohen CJ, Schmalhofer W, Smith M, Warren V, Garcia ML, Kaczorowski GJ.

Biochemistry. 1999 Aug 24;38(34):11137-46.

61.

Quantification and distribution of Ca(2+)-activated maxi K(+) channels in rabbit distal colon.

Grunnet M, Knaus HG, Solander C, Klaerke DA.

Am J Physiol. 1999 Jul;277(1 Pt 1):G22-30.

62.

High-conductance calcium-activated potassium channels in rat brain: pharmacology, distribution, and subunit composition.

Wanner SG, Koch RO, Koschak A, Trieb M, Garcia ML, Kaczorowski GJ, Knaus HG.

Biochemistry. 1999 Apr 27;38(17):5392-400.

63.

Scorpion toxins as tools for studying potassium channels.

Garcia ML, Hanner M, Knaus HG, Slaughter R, Kaczorowski GJ.

Methods Enzymol. 1999;294:624-39. Review.

64.

Purification and functional reconstitution of high-conductance calcium-activated potassium channel from smooth muscle.

Garcia ML, Giangiacomo KM, Hanner M, Knaus HG, McManus OB, Schmalhofer WA, Kaczorowski GJ.

Methods Enzymol. 1999;294:274-87. No abstract available.

65.

The beta subunit of the high conductance calcium-activated potassium channel. Identification of residues involved in charybdotoxin binding.

Hanner M, Vianna-Jorge R, Kamassah A, Schmalhofer WA, Knaus HG, Kaczorowski GJ, Garcia ML.

J Biol Chem. 1998 Jun 26;273(26):16289-96.

66.

Glucocorticoid regulation of calcium-activated potassium channels mediated by serine/threonine protein phosphatase.

Tian L, Knaus HG, Shipston MJ.

J Biol Chem. 1998 May 29;273(22):13531-6.

67.

Margatoxin increases dopamine release in rat striatum via voltage-gated K+ channels.

Saria A, Seidl CV, Fischer HS, Koch RO, Telser S, Wanner SG, Humpel C, Garcia ML, Knaus HG.

Eur J Pharmacol. 1998 Feb 19;343(2-3):193-200.

68.

Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom.

Koschak A, Bugianesi RM, Mitterdorfer J, Kaczorowski GJ, Garcia ML, Knaus HG.

J Biol Chem. 1998 Jan 30;273(5):2639-44.

70.

Increased expression of Ca2+-sensitive K+ channels in aorta of hypertensive rats.

Liu Y, Pleyte K, Knaus HG, Rusch NJ.

Hypertension. 1997 Dec;30(6):1403-9.

71.

Complex subunit assembly of neuronal voltage-gated K+ channels. Basis for high-affinity toxin interactions and pharmacology.

Koch RO, Wanner SG, Koschak A, Hanner M, Schwarzer C, Kaczorowski GJ, Slaughter RS, Garcia ML, Knaus HG.

J Biol Chem. 1997 Oct 31;272(44):27577-81.

72.

Molecular constituents of maxi KCa channels in human coronary smooth muscle: predominant alpha + beta subunit complexes.

Tanaka Y, Meera P, Song M, Knaus HG, Toro L.

J Physiol. 1997 Aug 1;502 ( Pt 3):545-57.

73.

The beta subunit of the high-conductance calcium-activated potassium channel contributes to the high-affinity receptor for charybdotoxin.

Hanner M, Schmalhofer WA, Munujos P, Knaus HG, Kaczorowski GJ, Garcia ML.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2853-8.

74.

Margatoxin binds to a homomultimer of K(V)1.3 channels in Jurkat cells. Comparison with K(V)1.3 expressed in CHO cells.

Helms LM, Felix JP, Bugianesi RM, Garcia ML, Stevens S, Leonard RJ, Knaus HG, Koch R, Wanner SG, Kaczorowski GJ, Slaughter RS.

Biochemistry. 1997 Mar 25;36(12):3737-44.

75.

[125I]Iberiotoxin-D19Y/Y36F, the first selective, high specific activity radioligand for high-conductance calcium-activated potassium channels.

Koschak A, Koch RO, Liu J, Kaczorowski GJ, Reinhart PH, Garcia ML, Knaus HG.

Biochemistry. 1997 Feb 18;36(7):1943-52.

76.

Pharmacology of potassium channels.

Garcia ML, Hanner M, Knaus HG, Koch R, Schmalhofer W, Slaughter RS, Kaczorowski GJ.

Adv Pharmacol. 1997;39:425-71. Review. No abstract available.

77.

Purification, molecular cloning, and expression of the mammalian sigma1-binding site.

Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H.

Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8072-7.

78.

High-conductance calcium-activated potassium channels; structure, pharmacology, and function.

Kaczorowski GJ, Knaus HG, Leonard RJ, McManus OB, Garcia ML.

J Bioenerg Biomembr. 1996 Jun;28(3):255-67. Review.

79.

Distribution of high-conductance Ca(2+)-activated K+ channels in rat brain: targeting to axons and nerve terminals.

Knaus HG, Schwarzer C, Koch RO, Eberhart A, Kaczorowski GJ, Glossmann H, Wunder F, Pongs O, Garcia ML, Sperk G.

J Neurosci. 1996 Feb 1;16(3):955-63.

80.

Functional reconstitution of the large-conductance, calcium-activated potassium channel purified from bovine aortic smooth muscle.

Giangiacomo KM, Garcia-Calvo M, Knaus HG, Mullmann TJ, Garcia ML, McManus O.

Biochemistry. 1995 Dec 5;34(48):15849-62.

 
81.

[125I]margatoxin, an extraordinarily high affinity ligand for voltage-gated potassium channels in mammalian brain.

Knaus HG, Koch RO, Eberhart A, Kaczorowski GJ, Garcia ML, Slaughter RS.

Biochemistry. 1995 Oct 17;34(41):13627-34.

82.

Characterization of tissue-expressed alpha subunits of the high conductance Ca(2+)-activated K+ channel.

Knaus HG, Eberhart A, Koch RO, Munujos P, Schmalhofer WA, Warmke JW, Kaczorowski GJ, Garcia ML.

J Biol Chem. 1995 Sep 22;270(38):22434-9.

83.

Charybdotoxin and its effects on potassium channels.

Garcia ML, Knaus HG, Munujos P, Slaughter RS, Kaczorowski GJ.

Am J Physiol. 1995 Jul;269(1 Pt 1):C1-10. Review.

85.

Purification and amino-terminal sequencing of the high affinity phenylalkylamine Ca2+ antagonist binding protein from guinea pig liver endoplasmic reticulum.

Moebius FF, Hanner M, Knaus HG, Weber F, Striessnig J, Glossmann H.

J Biol Chem. 1994 Nov 18;269(46):29314-20.

 
86.

Pharmacology and structure of high conductance calcium-activated potassium channels.

Knaus HG, Eberhart A, Glossmann H, Munujos P, Kaczorowski GJ, Garcia ML.

Cell Signal. 1994 Nov;6(8):861-70. Review. No abstract available.

87.

Primary sequence and immunological characterization of beta-subunit of high conductance Ca(2+)-activated K+ channel from smooth muscle.

Knaus HG, Folander K, Garcia-Calvo M, Garcia ML, Kaczorowski GJ, Smith M, Swanson R.

J Biol Chem. 1994 Jun 24;269(25):17274-8.

89.

Functional unit size of the charybdotoxin receptor in smooth muscle.

Garcia-Calvo M, Knaus HG, Garcia ML, Kaczorowski GJ, Kempner ES.

Proc Natl Acad Sci U S A. 1994 May 24;91(11):4718-22.

90.

Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium-activated potassium channels.

Knaus HG, McManus OB, Lee SH, Schmalhofer WA, Garcia-Calvo M, Helms LM, Sanchez M, Giangiacomo K, Reuben JP, Smith AB 3rd, et al.

Biochemistry. 1994 May 17;33(19):5819-28.

91.

Purification and reconstitution of the high-conductance, calcium-activated potassium channel from tracheal smooth muscle.

Garcia-Calvo M, Knaus HG, McManus OB, Giangiacomo KM, Kaczorowski GJ, Garcia ML.

J Biol Chem. 1994 Jan 7;269(1):676-82.

93.

Heterogeneity of L-type calcium channel alpha 1 subunits: stereoselective discrimination of different populations by the novel 1,4-dihydropyridine B 874-67.

Lakitsch M, Knaus HG, Topar G, Romanin C, Boer R, Flockerzi D, Striessnig J, Schindler H, Hoeltje HD, Glossmann H.

Mol Pharmacol. 1993 Feb;43(2):293-301.

94.

In vivo labeling of L-type Ca2+ channels by fluorescent dihydropyridines: evidence for a functional, extracellular heparin-binding site.

Knaus HG, Moshammer T, Friedrich K, Kang HC, Haugland RP, Glossman H.

Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3586-90.

95.

A unique fluorescent phenylalkylamine probe for L-type Ca2+ channels. Coupling of phenylalkylamine receptors to Ca2+ and dihydropyridine binding sites.

Knaus HG, Moshammer T, Kang HC, Haugland RP, Glossmann H.

J Biol Chem. 1992 Feb 5;267(4):2179-89.

 
96.

[35S]sadopine, a novel high affinity, high specific activity, L-type Ca2+ channel probe: characterization of two equipotent diastereomers with opposite allosteric properties.

Knaus HG, Striessnig J, Hering S, Marrer S, Schwenner E, Höltje HD, Glossmann H.

Mol Pharmacol. 1992 Feb;41(2):298-307.

97.

Complex allosteric interaction of heparin with neurokinin-1 receptors.

Knaus GA, Knaus HG, Saria A.

Eur J Pharmacol. 1991 Jul 12;207(3):267-70.

98.

Calcium channels from Cyprinus carpio skeletal muscle.

Grabner M, Friedrich K, Knaus HG, Striessnig J, Scheffauer F, Staudinger R, Koch WJ, Schwartz A, Glossmann H.

Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):727-31.

100.

Neurokinin-1 receptors in the human eye. Characterization and autoradiographic distribution.

Kieselbach GF, Ragaut R, Knaus HG, König P, Saria A, Wiedermann CJ.

Ann N Y Acad Sci. 1991;632:466-7. No abstract available.

 
 
101.

Allosteric interaction of heparin with NK-1 receptors in rat striatal membranes.

Knaus GA, Knaus HG, Saria A.

Ann N Y Acad Sci. 1991;632:422-5. No abstract available.

102.

Heparin binds with high affinity to voltage-dependent L-type Ca2+ channels. Evidence for an agonistic action.

Knaus HG, Scheffauer F, Romanin C, Schindler HG, Glossmann H.

J Biol Chem. 1990 Jul 5;265(19):11156-66.

103.

Autoradiographic analysis of binding sites for 125I-Bolton-Hunter-substance P in the human eye.

Kieselbach GF, Ragaut R, Knaus HG, König P, Wiedermann CJ.

Peptides. 1990 Jul-Aug;11(4):655-9.

104.

[3H]HOE166 defines a novel calcium antagonist drug receptor--distinct from the 1,4 dihydropyridine binding domain.

Grassegger A, Striessnig J, Weiler M, Knaus HG, Glossmann H.

Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6 Pt 2):752-9.

106.

Structure of calcium channels.

Glossmann H, Striessnig J, Knaus HG, Müller J, Grassegger A, Höltje HD, Marrer S, Hymel L, Schindler HG.

Ann N Y Acad Sci. 1989;560:198-214. Review. No abstract available.

107.
108.

Evidence for a distinct Ca2+ antagonist receptor for the novel benzothiazinone compound HOE 166.

Striessnig J, Meusburger E, Grabner M, Knaus HG, Glossmann H, Kaiser J, Schölkens B, Becker R, Linz W, Henning R.

Naunyn Schmiedebergs Arch Pharmacol. 1988 Mar;337(3):331-40.

 
109.

Neurotoxic aminoglycoside antibiotics are potent inhibitors of [125I]-Omega-Conotoxin GVIA binding to guinea-pig cerebral cortex membranes.

Knaus HG, Striessnig J, Koza A, Glossmann H.

Naunyn Schmiedebergs Arch Pharmacol. 1987 Nov;336(5):583-6.

 
110.

Identification of a novel 1,4-dihydropyridine- and phenylalkylamine-binding polypeptide in calcium channel preparations.

Vaghy PL, Striessnig J, Miwa K, Knaus HG, Itagaki K, McKenna E, Glossmann H, Schwartz A.

J Biol Chem. 1987 Oct 15;262(29):14337-42.

 
111.

Photoaffinity labelling of the phenylalkylamine receptor of the skeletal muscle transverse-tubule calcium channel.

Striessnig J, Knaus HG, Grabner M, Moosburger K, Seitz W, Lietz H, Glossmann H.

FEBS Lett. 1987 Feb 23;212(2):247-53.

© Medizinische Universität Innsbruck - Alle Rechte vorbehaltenMail an i-master - Letzte Änderung: 6.2.2017, 14:00:09ximsTwitter LogoFacebook Logo